Tiara is the front runner device in the mitral valve space, which is an untapped market that is estimated to be 2x-4x the size of the aortic valve market. A lot is at stake here.
Neovasc is also in the midst of a limited commercial launch of its Reducer device in Europe, which helps relieve patients suffering from refractory angina. Revenues jumped 429% in Q1 to $213K. It will take a few years for Reducer to generate meaningful revenue.
The real catalyst to boost Neovasc shares from current depressed levels is positive data presented at the Transcatheter Valve Therapies meeting. Neovasc presents June 16. Based on the previous successful implants of the Tiara, the data is expected to be positive. At this point, given the unknowns regarding the trial damages and patent ownership, this is an extremely speculative play. But there is still upside potential if NVCN presents positive Tiara data at TVT meeting, and
if the judge rules favorably for NVCN by either A) reducing $70M penalty, B) ruling against CardiAq RE: claims to ownership of Tiara, or C) both.
Leerink note below (from May 2016)